Pregnant and nursing women. Products, Dosage, and Mode of Administration: Investigational Products Dosage Mode of Administration Aldoxorubicin HCl 80 mg/m2 (induction); 60 mg/m2 (maintenance) IV ALT -803 15 µg/kg SC ETBX -011 (CEA) 1 × 1011 VP/dose SC ETBX -051 (Brachyury) 1 × 1011 VP/dose SC ETBX -061 (MUC1) 1 × 1011 VP/dose SC GI-4000 (RAS) 40 YU/dose SC GI-6207 (CEA) 40 YU/dose SC GI-6301 (Brachyury) 40 YU/dose SC haNK cells 2 × 109 cells/dose IV Approved Products Dosage Mode of Administration Avelumab 10 mg/kg IV Bevacizumab 5 mg/kg IV Capecitabine 650 mg/m2 BID , up to a maximum of 1,000 mg per dose PO Cisplatin 40 mg/m2 (day 1); 20 mg/m2 (day 8) IV NANT TNBC Vaccine NantKwest, Inc. Clinical Trial Protocol: QUILT -3.067 Amendment 3 Confidential and Proprietary 13 Cyclophosphamide 25 mg BID (days 1 –5) 25 mg daily (days 8 –12) PO 5-FU 1500 mg/m2 85- to 96-hour continuous IV infusion Leucovorin 20 mg/m2 IV bolus Nab-paclitaxel 125 mg (induction); 100 mg (maintenance) IV SBRT 8 Gy maximum (exact dose to be determined by the radiation oncologist) External beam radiation Duration of Treatment: • Induction phase: Up to 1 year. • Maintenance phase: Up to 1 year.